Please assess the completion status of the following clinical trial:

Trial Title: Study of Ataluren (PTC124) in Cystic Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ability to provide written informed consent (parental/guardian consent and participant assent if less than \[\<\] 18 years of age).~* Evidence of completed participation in the double-blind study, PTC124-GD-009-CF (Study 009).~* Body weight greater than or equal to (≥) 16 kilograms (kg).~* Performance of a valid, reproducible spirometry test using the study-specific spirometer during the screening period.~* Confirmed laboratory values within the central laboratory ranges at screening.~* In male and female participants who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and 60-day follow-up period.~* Willingness and ability to comply with all study procedures and assessments, including scheduled visits, drug administration plan, laboratory tests, and study restrictions.~Key Exclusion Criteria:~* Chronic use of systemic tobramycin within 4 weeks prior to screening.~* Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 3 weeks prior to screening or between screening and randomization.~* Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or re-initiation) in a chronic treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks prior to screening and randomization.~* Known hypersensitivity to any of the ingredients or excipients of the study drug.~* Exposure to another investigational drug within 4 weeks prior to screening.~* Treatment with intravenous antibiotics within 3 weeks prior to screening.~* History of solid organ or hematological transplantation.~* Ongoing immunosuppressive therapy (other than corticosteroids).~* Positive hepatitis B surface antigen, hepatitis C antibody test or human immunodeficiency virus (HIV) test.~* Known portal hypertension.~* Pregnancy or breast-feeding.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ataluren (Type: EXPERIMENTAL): Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 192 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).